Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hyperpolarized 13C Pyruvate Metabolic MRI to Predict Renal Tumor Aggressiveness

NCT04258462 is registered in ClinicalTrials.gov with Zhen Wang, MD as lead sponsor.

NCT NCT04258462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04258462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hyperpolarized 13C Pyruvate Metabolic MRI to Predict Renal Tumor Aggressiveness
Lead sponsor
Zhen Wang, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 15, 2019
Completion date
October 31, 2026
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

benign kidney neoplasm, kidney neoplasm, renal cell cancer